Interleukin 6 promotes murine lupus in NZB/NZW F1 mice (original) (raw)

Abstract

To investigate the role of IL-6 in systemic lupus erythematosus (SLE), we selectively inhibited IL-6 in lupus-prone NZB/NZW F1(B/W) mice by chronic administration of a rat mAb to mouse IL-6. Anti-IL-6 alone elicited an anti-rat response that blocked its biologic effects. To circumvent this problem, we rendered B/W mice tolerant to the rat mAb by administration of anti-CD4 concurrent with the first dose of anti-IL-6. Thereafter, the mice received weekly injections of anti-IL-6 alone. There were two control groups: one group received the tolerizing regimen of anti-CD4 along with a control rat IgG1 mAb (GL113) instead of anti-IL-6; the other control group received PBS. Mice that received anti-CD4 were tolerant to the rat mAb for 6 mo. Throughout this period, treatment with anti-IL-6 prevented production of anti-dsDNA, significantly reduced proteinuria, and prolonged life. Mice that received anti-IL-6 without anti-CD4 developed an immune response to the rat mAb and then developed anti-dsDNA antibodies, proteinuria, and mortality comparable with control mice. These findings establish that IL-6 promotes autoimmunity in B/W mice. They further indicate that, although mAb to IL-6 can suppress murine lupus, the development of host immunity to the mAb abrogates its beneficial effects. Finally, this is the first study to demonstrate that a brief course of anti-CD4 can induce tolerance to another therapeutic mAb, in this case an anti-cytokine mAb.

585

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Alarcón-Riquelme M. E., Möller G., Fernández C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. Clin Immunol Immunopathol. 1992 Mar;62(3):264–269. doi: 10.1016/0090-1229(92)90101-s. [DOI] [PubMed] [Google Scholar]
  3. Alarcón-Riquelme M. E., Möller G., Fernández C. Macrophage depletion decreases IgG anti-DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol. 1993 Feb;91(2):220–225. doi: 10.1111/j.1365-2249.1993.tb05886.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baumann H., Jahreis G. P., Sauder D. N., Koj A. Human keratinocytes and monocytes release factors which regulate the synthesis of major acute phase plasma proteins in hepatic cells from man, rat, and mouse. J Biol Chem. 1984 Jun 10;259(11):7331–7342. [PubMed] [Google Scholar]
  5. Benjamin R. J., Cobbold S. P., Clark M. R., Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med. 1986 Jun 1;163(6):1539–1552. doi: 10.1084/jem.163.6.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Benjamin R. J., Qin S. X., Wise M. P., Cobbold S. P., Waldmann H. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol. 1988 Jul;18(7):1079–1088. doi: 10.1002/eji.1830180717. [DOI] [PubMed] [Google Scholar]
  7. Campbell I. L., Harrison L. C. A new view of the beta cell as an antigen-presenting cell and immunogenic target. J Autoimmun. 1990 Apr;3 (Suppl 1):53–62. doi: 10.1016/s0896-8411(09)90010-5. [DOI] [PubMed] [Google Scholar]
  8. Campbell I. L., Harrison L. C. Molecular pathology of type 1 diabetes. Mol Biol Med. 1990 Aug;7(4):299–309. [PubMed] [Google Scholar]
  9. Campbell I. L., Kay T. W., Oxbrow L., Harrison L. C. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest. 1991 Feb;87(2):739–742. doi: 10.1172/JCI115055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carteron N. L., Schimenti C. L., Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 1;142(5):1470–1475. [PubMed] [Google Scholar]
  11. Corbel C., Melchers F. The synergism of accessory cells and of soluble alpha-factors derived from them in the activation of B cells to proliferation. Immunol Rev. 1984 Apr;78:51–74. doi: 10.1111/j.1600-065x.1984.tb00476.x. [DOI] [PubMed] [Google Scholar]
  12. Emmendörffer A., Müller M., Wedekind D., Hartung K., Lohmann-Matthes M. L. Expansion of the liver-associated macrophage system in systemic lupus erythematosus-prone NZB/W mice. J Leukoc Biol. 1993 Mar;53(3):294–300. doi: 10.1002/jlb.53.3.294. [DOI] [PubMed] [Google Scholar]
  13. Freeman G. J., Freedman A. S., Rabinowe S. N., Segil J. M., Horowitz J., Rosen K., Whitman J. F., Nadler L. M. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May;83(5):1512–1518. doi: 10.1172/JCI114046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gordon C., Richards N., Howie A. J., Richardson K., Michael J., Adu D., Emery P. Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol. 1991 Oct;86(1):145–149. doi: 10.1111/j.1365-2249.1991.tb05787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gutstein N. L., Seaman W. E., Scott J. H., Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15;137(4):1127–1132. [PubMed] [Google Scholar]
  17. Gutstein N. L., Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 1;137(11):3414–3419. [PubMed] [Google Scholar]
  18. Herron L. R., Coffman R. L., Kotzin B. L. Enhanced response of autoantibody-secreting B cells from young NZB/NZW mice to T-cell-derived differentiation signals. Clin Immunol Immunopathol. 1988 Feb;46(2):314–327. doi: 10.1016/0090-1229(88)90193-6. [DOI] [PubMed] [Google Scholar]
  19. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldmann M. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988 Nov;18(11):1797–1801. doi: 10.1002/eji.1830181122. [DOI] [PubMed] [Google Scholar]
  20. Hirano T., Taga T., Nakano N., Yasukawa K., Kashiwamura S., Shimizu K., Nakajima K., Pyun K. H., Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490–5494. doi: 10.1073/pnas.82.16.5490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hirano T., Taga T., Yasukawa K., Nakajima K., Nakano N., Takatsuki F., Shimizu M., Murashima A., Tsunasawa S., Sakiyama F. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 1987 Jan;84(1):228–231. doi: 10.1073/pnas.84.1.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hirano T., Teranishi T., Lin B., Onoue K. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowan I-stimulated B cells. J Immunol. 1984 Aug;133(2):798–802. [PubMed] [Google Scholar]
  23. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986 Nov 6;324(6092):73–76. doi: 10.1038/324073a0. [DOI] [PubMed] [Google Scholar]
  24. Hirohata S., Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990 May;33(5):644–649. doi: 10.1002/art.1780330506. [DOI] [PubMed] [Google Scholar]
  25. Hirose T., Hara M., Kitani A., Hirose W., Norioka K., Kawagoe M., Nakamura H. Abnormal production of and response to B-cell growth factor and B-cell differentiation factor in patients with systemic lupus erythematosus. Scand J Immunol. 1985 Feb;21(2):141–150. doi: 10.1111/j.1365-3083.1985.tb01413.x. [DOI] [PubMed] [Google Scholar]
  26. Horii Y., Muraguchi A., Iwano M., Matsuda T., Hirayama T., Yamada H., Fujii Y., Dohi K., Ishikawa H., Ohmoto Y. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989 Dec 15;143(12):3949–3955. [PubMed] [Google Scholar]
  27. Horii Y., Muraguchi A., Suematsu S., Matsuda T., Yoshizaki K., Hirano T., Kishimoto T. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol. 1988 Sep 1;141(5):1529–1535. [PubMed] [Google Scholar]
  28. Houssiau F. A., Devogelaer J. P., Van Damme J., de Deuxchaisnes C. N., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988 Jun;31(6):784–788. doi: 10.1002/art.1780310614. [DOI] [PubMed] [Google Scholar]
  29. Hültner L., Szöts H., Welle M., Van Snick J., Moeller J., Dörmer P. Mouse bone marrow-derived IL-3-dependent mast cells and autonomous sublines produce IL-6. Immunology. 1989 Jul;67(3):408–413. [PMC free article] [PubMed] [Google Scholar]
  30. Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9035–9039. doi: 10.1073/pnas.84.24.9035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Isaacs J. D. The antiglobulin response to therapeutic antibodies. Semin Immunol. 1990 Nov;2(6):449–456. [PubMed] [Google Scholar]
  32. Izui S., McConahey P. J., Dixon F. J. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol. 1978 Dec;121(6):2213–2219. [PubMed] [Google Scholar]
  33. Kitani A., Hara M., Hirose T., Harigai M., Suzuki K., Kawakami M., Kawaguchi Y., Hidaka T., Kawagoe M., Nakamura H. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992 Apr;88(1):75–83. doi: 10.1111/j.1365-2249.1992.tb03042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kitani A., Hara M., Hirose T., Norioka K., Harigai M., Hirose W., Suzuki K., Kawakami M., Kawagoe M., Nakamura H. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol. 1989 Jul;77(1):31–36. [PMC free article] [PubMed] [Google Scholar]
  35. Klinman D. M., Steinberg A. D. Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med. 1987 Jun 1;165(6):1755–1760. doi: 10.1084/jem.165.6.1755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992 Apr;63(1):10–12. doi: 10.1016/0090-1229(92)90084-2. [DOI] [PubMed] [Google Scholar]
  37. Linker-Israeli M., Deans R. J., Wallace D. J., Prehn J., Ozeri-Chen T., Klinenberg J. R. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991 Jul 1;147(1):117–123. [PubMed] [Google Scholar]
  38. MacCarthy E. P., Hsu A., Ooi Y. M., Ooi B. S. Modulation of mouse mesangial cell proliferation by macrophage products. Immunology. 1985 Dec;56(4):695–699. [PMC free article] [PubMed] [Google Scholar]
  39. Metsärinne K. P., Nordström D. C., Konttinen Y. T., Teppo A. M., Fyhrquist F. Y. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int. 1992;12(3):93–96. doi: 10.1007/BF00290261. [DOI] [PubMed] [Google Scholar]
  40. Mihara M., Fukui H., Koishihara Y., Saito M., Ohsugi Y. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol. 1990 Dec;82(3):533–537. doi: 10.1111/j.1365-2249.1990.tb05485.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988 Feb 1;167(2):332–344. doi: 10.1084/jem.167.2.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Okada M., Kitahara M., Kishimoto S., Matsuda T., Hirano T., Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988 Sep 1;141(5):1543–1549. [PubMed] [Google Scholar]
  43. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983 Dec;131(6):2895–2902. [PubMed] [Google Scholar]
  44. Pelton B. K., Hylton W., Denman A. M. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 1992 Aug;89(2):251–254. doi: 10.1111/j.1365-2249.1992.tb06940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Seaman W. E., Wofsy D., Greenspan J. S., Ledbetter J. A. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr;130(4):1713–1718. [PubMed] [Google Scholar]
  46. Spronk P. E., ter Borg E. J., Limburg P. C., Kallenberg C. G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992 Oct;90(1):106–110. doi: 10.1111/j.1365-2249.1992.tb05840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Staples P. J., Steinberg A. D., Talal N. Induction of immunologic tolerance in older New Zealand mice repopulated with young spleen, bone marrow, or thymus. J Exp Med. 1970 Jun 1;131(6):1223–1238. doi: 10.1084/jem.131.6.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Staples P. J., Talal N. Rapid loss of tolerance induced in weanling NZB and B-W F1 mice. Science. 1969 Mar 14;163(3872):1215–1216. doi: 10.1126/science.163.3872.1215. [DOI] [PubMed] [Google Scholar]
  49. Staples P. J., Talal N. Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med. 1969 Jan 1;129(1):123–139. doi: 10.1084/jem.129.1.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Starnes H. F., Jr, Pearce M. K., Tewari A., Yim J. H., Zou J. C., Abrams J. S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed] [Google Scholar]
  51. Steward M. W., Hay F. C. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clin Exp Immunol. 1976 Nov;26(2):363–370. [PMC free article] [PubMed] [Google Scholar]
  52. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki J., Yamamura K., Hirano T., Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547–7551. doi: 10.1073/pnas.86.19.7547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Swaak A. J., van Rooyen A., Aarden L. A. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989;8(6):263–268. doi: 10.1007/BF00270982. [DOI] [PubMed] [Google Scholar]
  54. Takai Y., Wong G. G., Clark S. C., Burakoff S. J., Herrmann S. H. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol. 1988 Jan 15;140(2):508–512. [PubMed] [Google Scholar]
  55. Tanaka Y., Saito K., Shirakawa F., Ota T., Suzuki H., Eto S., Yamashita U. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol. 1988 Nov 1;141(9):3043–3049. [PubMed] [Google Scholar]
  56. Tang B., Matsuda T., Akira S., Nagata N., Ikehara S., Hirano T., Kishimoto T. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol. 1991 Mar;3(3):273–278. doi: 10.1093/intimm/3.3.273. [DOI] [PubMed] [Google Scholar]
  57. Van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie P. G., Rubira M. R., Simpson R. J. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9679–9683. doi: 10.1073/pnas.83.24.9679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Vandenabeele P., Abramowicz D., Berus D., Van der Heyden J., Grooten J., Donckier V., Hooghe-Peters E. L., Goldman M., Fiers W. Increased IL-6 production and IL-6-mediated Ig secretion in murine host-vs-graft disease. J Immunol. 1993 May 1;150(9):4179–4187. [PubMed] [Google Scholar]
  59. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Soreq H., Nir U., Wallach D., Perricaudet M., Tiollais P., Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7152–7156. doi: 10.1073/pnas.77.12.7152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993 Feb;20(2):259–262. [PubMed] [Google Scholar]
  61. Wofsy D., Seaman W. E. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987 May 15;138(10):3247–3253. [PubMed] [Google Scholar]
  62. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Wong G. G., Witek-Giannotti J. S., Temple P. A., Kriz R., Ferenz C., Hewick R. M., Clark S. C., Ikebuchi K., Ogawa M. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 1988 May 1;140(9):3040–3044. [PubMed] [Google Scholar]
  64. Woodroofe C., Müller W., Rüther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992 Oct;11(8):587–592. doi: 10.1089/dna.1992.11.587. [DOI] [PubMed] [Google Scholar]
  65. al-Janadi M., al-Balla S., al-Dalaan A., Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993 Jan;13(1):58–67. doi: 10.1007/BF00920636. [DOI] [PubMed] [Google Scholar]